Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Saturday, May 26, 2018 · 448,804,145 Articles · 3+ Million Readers

Glycoprotein 41 Therapeutic and Overview Pipeline Review H2



Glycoprotein 41 Treatment Pipeline Review H2 2016

PUNE, INDIA, November 14, 2016 / -- The report provides comprehensive information on the Glycoprotein 41 (gp41), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glycoprotein 41 (gp41) targeted therapeutics development and features dormant and discontinued projects.

Get Sample Report @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

- The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)
- The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Glycoprotein 41 (gp41) Overview 8
Therapeutics Development 9
Glycoprotein 41 (gp41) - Products under Development by Stage of Development 9
Glycoprotein 41 (gp41) - Products under Development by Therapy Area 10
Glycoprotein 41 (gp41) - Products under Development by Indication 11
Glycoprotein 41 (gp41) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Glycoprotein 41 (gp41) - Products under Development by Companies 14
Glycoprotein 41 (gp41) - Products under Development by Universities/Institutes 16
Glycoprotein 41 (gp41) - Therapeutics Assessment 18
Assessment by Monotherapy/Combination Products 18
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development 24
Amunix Operating Inc. 24
BioClonetics Immunotherapeutics, Inc. 25
ConjuChem, LLC 26
Frontier Biotechnologies Co., Ltd 27
InnaVirVax SA 28
Longevity Biotech, Inc 29
Mymetics Corporation 30
Navigen Pharmaceuticals, Inc. 31
Osel, Inc. 32
Pharis Biotec GmbH 33
Glycoprotein 41 (gp41) - Drug Profiles 34
Biologic for Infectious Disease - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
CLONE-3 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
CPT-31 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
DAC-HIV - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38

Access Report @

Get in touch:

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire